J Aller Cl Imm-Pract:哮喘、鼻窦疾病与活动性肺结核风险

2018-09-10 xing.T MedSci原创

由此可见,哮喘或鼻窦疾病病史可调节免疫应答,以降低成年人群中活动性结核病的发病率。

尽管哮喘与肺部免疫功能受损有关,但尚不清楚哮喘是否会影响活动性肺结核(TB)的风险。由于上呼吸道和下呼吸道具有免疫学相关性,鼻窦疾病也可能改变对结核病的易感性。 近日,过敏性疾病领域权威杂志Journal of Allergy and Clinical Immunology-In Practice上发表了一篇研究文章,在新加坡华人健康研究中,研究人员旨在评估哮喘和鼻窦疾病是否可以前瞻性地调节活动性结核病的风险。

在这个以人群为基础的前瞻性队列中,研究人员从1993年至1998年期间在新加坡招募了63257名45-74岁的成年华人,并在1999 - 2004年期间对52325名幸存的参与者进行了随访。在基线时收集关于医生诊断的鼻窦疾病患者自我报告病史的数据,并且在随访访谈中收集了关于哮喘和慢性支气管炎的数据。在2014年12月之前,通过与国家结核病通报登记处联系确定了活动性结核病例。研究人员使用多变量Cox比例风险回归模型估计了活动性结核病的风险。

在受试者招募后平均17年的随访期间,共有1249例活动性结核病患者,其中在12年的随访访视期间诊断出678例病例。研究人员观察到随访期间发生哮喘 [风险比(HR)为0.55,95%置信区间(CI)为0.32-0.93]或基线时鼻腔鼻窦疾病(HR为0.59,95%CI为0.36-0.95)的患者活动性结核病风险降低。相反,慢性支气管炎病史与结核病风险无关(HR为0.95,95%CI为0.68-1.31)。

由此可见,哮喘或鼻窦疾病病史可调节免疫应答,以降低成年人群中活动性结核病的发病率。

原始出处:

Anthony C. Yii,et al. Asthma, sinonasal disease, and the risk of active tuberculosis. J Aller Cl Imm-Pract. 2018. https://doi.org/10.1016/j.jaip.2018.07.036

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1717397, encodeId=c3381e173977a, content=<a href='/topic/show?id=19e3651804a' target=_blank style='color:#2F92EE;'>#活动性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65180, encryptionId=19e3651804a, topicName=活动性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc6532392545, createdName=guguangxiang, createdTime=Mon Jul 22 18:21:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723937, encodeId=837b1e239375e, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Jul 02 13:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345003, encodeId=802f34500357, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Fri Sep 14 21:56:26 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254211, encodeId=1441125421150, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329152, encodeId=b7b31329152bc, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344373, encodeId=a16e3443e337, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 10 15:45:17 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344370, encodeId=a9993443e04c, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Sep 10 14:56:45 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1717397, encodeId=c3381e173977a, content=<a href='/topic/show?id=19e3651804a' target=_blank style='color:#2F92EE;'>#活动性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65180, encryptionId=19e3651804a, topicName=活动性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc6532392545, createdName=guguangxiang, createdTime=Mon Jul 22 18:21:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723937, encodeId=837b1e239375e, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Jul 02 13:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345003, encodeId=802f34500357, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Fri Sep 14 21:56:26 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254211, encodeId=1441125421150, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329152, encodeId=b7b31329152bc, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344373, encodeId=a16e3443e337, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 10 15:45:17 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344370, encodeId=a9993443e04c, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Sep 10 14:56:45 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1717397, encodeId=c3381e173977a, content=<a href='/topic/show?id=19e3651804a' target=_blank style='color:#2F92EE;'>#活动性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65180, encryptionId=19e3651804a, topicName=活动性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc6532392545, createdName=guguangxiang, createdTime=Mon Jul 22 18:21:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723937, encodeId=837b1e239375e, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Jul 02 13:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345003, encodeId=802f34500357, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Fri Sep 14 21:56:26 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254211, encodeId=1441125421150, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329152, encodeId=b7b31329152bc, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344373, encodeId=a16e3443e337, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 10 15:45:17 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344370, encodeId=a9993443e04c, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Sep 10 14:56:45 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
    2018-09-14 一一一多

    学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1717397, encodeId=c3381e173977a, content=<a href='/topic/show?id=19e3651804a' target=_blank style='color:#2F92EE;'>#活动性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65180, encryptionId=19e3651804a, topicName=活动性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc6532392545, createdName=guguangxiang, createdTime=Mon Jul 22 18:21:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723937, encodeId=837b1e239375e, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Jul 02 13:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345003, encodeId=802f34500357, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Fri Sep 14 21:56:26 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254211, encodeId=1441125421150, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329152, encodeId=b7b31329152bc, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344373, encodeId=a16e3443e337, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 10 15:45:17 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344370, encodeId=a9993443e04c, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Sep 10 14:56:45 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1717397, encodeId=c3381e173977a, content=<a href='/topic/show?id=19e3651804a' target=_blank style='color:#2F92EE;'>#活动性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65180, encryptionId=19e3651804a, topicName=活动性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc6532392545, createdName=guguangxiang, createdTime=Mon Jul 22 18:21:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723937, encodeId=837b1e239375e, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Jul 02 13:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345003, encodeId=802f34500357, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Fri Sep 14 21:56:26 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254211, encodeId=1441125421150, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329152, encodeId=b7b31329152bc, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344373, encodeId=a16e3443e337, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 10 15:45:17 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344370, encodeId=a9993443e04c, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Sep 10 14:56:45 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
    2018-09-12 膀胱癌
  6. [GetPortalCommentsPageByObjectIdResponse(id=1717397, encodeId=c3381e173977a, content=<a href='/topic/show?id=19e3651804a' target=_blank style='color:#2F92EE;'>#活动性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65180, encryptionId=19e3651804a, topicName=活动性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc6532392545, createdName=guguangxiang, createdTime=Mon Jul 22 18:21:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723937, encodeId=837b1e239375e, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Jul 02 13:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345003, encodeId=802f34500357, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Fri Sep 14 21:56:26 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254211, encodeId=1441125421150, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329152, encodeId=b7b31329152bc, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344373, encodeId=a16e3443e337, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 10 15:45:17 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344370, encodeId=a9993443e04c, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Sep 10 14:56:45 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
    2018-09-10 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1717397, encodeId=c3381e173977a, content=<a href='/topic/show?id=19e3651804a' target=_blank style='color:#2F92EE;'>#活动性肺结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65180, encryptionId=19e3651804a, topicName=活动性肺结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cc6532392545, createdName=guguangxiang, createdTime=Mon Jul 22 18:21:00 CST 2019, time=2019-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723937, encodeId=837b1e239375e, content=<a href='/topic/show?id=2d996516e7c' target=_blank style='color:#2F92EE;'>#活动性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65167, encryptionId=2d996516e7c, topicName=活动性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596833562866, createdName=楚秀娟, createdTime=Tue Jul 02 13:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=345003, encodeId=802f34500357, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/eiadcQaiaZ4fUvicZKEbibPBA2otZ0yzMeAVET5icsaS77W0Tvo3ibFMibzxTVRPsg62xJu0GicwBCvAlPMyu7TB6j86ug/132, createdBy=d64c1981665, createdName=一一一多, createdTime=Fri Sep 14 21:56:26 CST 2018, time=2018-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254211, encodeId=1441125421150, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329152, encodeId=b7b31329152bc, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Sep 12 05:21:00 CST 2018, time=2018-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344373, encodeId=a16e3443e337, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Sep 10 15:45:17 CST 2018, time=2018-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=344370, encodeId=a9993443e04c, content=学习知识了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Mon Sep 10 14:56:45 CST 2018, time=2018-09-10, status=1, ipAttribution=)]
    2018-09-10 flysky120

    学习知识了,谢谢

    0

相关资讯

Medicine:孟鲁司特联合布地奈德治疗慢性咳嗽变异性哮喘患儿的效果

本研究旨在探究孟鲁司特联合布地奈德(MCB)治疗慢性咳嗽变异性哮喘(CCVA)儿童的有效性和安全性。研究共纳入82例CCVA患儿,年龄4~11岁。所有病例在2015年5月至2017年4月期间接受MCB或仅接受布地奈德治疗。主要结果是肺功能,通过呼气峰流速(PEFR)和1秒钟用力呼气量(FEV1)来评估。次要结果通过临床评估评分来衡量。此外,本研究还记录了不良事件(AEs)的发生。治疗8周后评估所有

阿斯利康哮喘新药tezepelumab获得美国FDA突破性疗法认定

阿斯利康和安进近日宣布,FDA授予了tezepelumab突破性疗法认定,用于治疗没有嗜酸性粒细胞表型的严重哮喘患者。阿斯利康首席医疗官肖恩·博恩(Sean Bohen)表示,这种阻断上皮细胞因子的药物是令人兴奋,因为它有可能治疗更广泛的重症哮喘患者。FDA的这一决定是基于IIb期PATHWAY研究的数据,阿斯利康和安进去年报告这项研究符合其主要临床终点。

Lancet Psychiat:儿童多动症与哮喘存在“明显”关联

英国南安普敦大学领衔开展的一项新研究发现,儿童多动症与哮喘之间存在“明显”关联,这项结果可能会对两种疾病的临床处置产生重要影响,并有望带来对多动症病理生理学的新见解。多动症,又称注意力缺陷多动障碍,是儿童时期常见的一类行为障碍,主要表现为与年龄和发育水平不相称的注意力不集中、活动过度、情绪冲动等。哮喘是一种常见的气道慢性炎症,常导致喘息、气促、胸闷等症状。南安普敦大学等机构研究人员在英国《柳叶刀·

Eur Ann Allergy Clin Immunol :过敏症对患有注意力缺陷多动障碍儿童的影响

注意力缺陷多动障碍(ADHD)在全世界范围内常见,并对那些受影响的患者造成了严重的问题。ADHD从属于过敏障碍或者过敏障碍医药治疗。ADHD和过敏均依赖于复杂的环境和遗传互作,并且它们还满足超敏反应标准。最近,有研究人员在ADHD儿童中检测了过敏的占比,包括常见的过敏障碍和过敏原,以及过敏对ADHD症状和严重度的影响。研究包括了100名患有ADHD的儿童,并进行精神病评估,从而了解ADHD类型和严

一般剂量药物无效 重症哮喘特殊临床类型一例

哮喘持续状态(Status asthmatics)或称哮喘严重发作系指哮喘急性严重发作,经合理应用一般剂量的β2受体激动剂和氨茶碱不见缓解,病情进行性加重者。本病属于重症哮喘的一种特殊临床类型,由于严重的支气管痉挛,过度的粘液分泌和气道炎症、水肿可致明显的通气功能障碍,如不及时治疗可发展至呼吸衰竭甚至死亡,是临床急症之一。

BMC Pregnancy and Childbirth:母乳喂养或能降低高风险儿童的哮喘患病率

最近发表在开放获取期刊《BMC妊娠与生育》(BMC Pregnancy and Childbirth)上的一项研究发现,如果母亲孕期使用过抗生素,孩子患哮喘的风险会升高,但如果母亲能够在孩子出生后的6个月内进行纯母乳喂养,这种风险就会被降低。